Metformin May Extend Longevity for Older Women, Study Finds
A study of 438 postmenopausal women with type 2 diabetes suggests that starting metformin is associated with about a 30% lower risk of dying before age 90 compared with sulfonylurea therapy, hinting at metformin's potential aging‑related benefits. However, the findings are observational (not randomized), with no placebo group and a modest sample size; the long follow‑up of 14–15 years strengthens the signal but cannot prove causality, and randomized trials are needed to confirm longevity effects.
